J.P. Morgan analyst Anupam Rama has maintained their bullish stance on SRPT stock, giving a Buy rating today.
Claim 55% Off TipRanks
New trading tool for SRPT bullsAnupam Rama’s rating is based on several strategic developments at Sarepta Therapeutics that indicate a positive outlook for the company. The recent updates from Sarepta have removed worst-case scenarios, such as the potential market withdrawal of Elevidys, which now carries a black box warning for certain patients. This development is seen as a positive step in stabilizing the company’s position and is expected to boost investor sentiment.
Anupam Rama also highlights Sarepta’s strategic restructuring efforts, which aim to significantly reduce operational expenses and save approximately $400 million annually. This cost management, combined with the company’s focus on promising siRNA programs and the long-term potential of its commercial franchises, supports the Buy rating. The anticipated revenue stability and strategic pipeline efforts further reinforce confidence in Sarepta’s future performance.
In another report released today, Mizuho Securities also maintained a Buy rating on the stock with a $40.00 price target.
SRPT’s price has also changed dramatically for the past six months – from $117.060 to $18.380, which is a -84.30% drop .